A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs RPL 554 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 27 Jul 2017 The first patients have been dosed in this trial, according to a Verona Pharma media release.
- 16 Jul 2017 Status changed from planning to recruiting.
- 03 Jul 2017 New trial record